We propose to establish an Antibody Core at the Rockefeller University which will serve as an antibody resource for investigators participating in the ADCC. The initial focus of the Core will be to produce, store and provide antibodies relevant to the study of APP and Abeta. Much of our understanding of the processing of APP, the production of Abeta, and the formation of insoluble Abeta-amyloid has depended on experiments carried out using well-defined antibodies. Furthermore, such antibodies have also been extensively used to examine the neuropathological progression of Abeta-amyloidosis. The recent discovery of APP-related proteins which cross-react with anti-APP antibodies but are not a source of Abeta makes the development of APP-specific antibodies particularly important. We propose to prepare a large panel of monoclonal antibodies with defined properties to be used for studies of APP processing. Abeta production, and Abeta amyloidogenesis. The establishment of this Antibody Core will provide valuable support to researchers at Rockefeller, NYU, IBR and NKI who are participating in the ADCC, as well as to scientists at other ADCs. Studies using core resources will be more cost effective, and in some instances projects will be conducted that would not be feasible without the availability of these antibodies. Establishment of this Core also will strengthen the involvement of The Rockefeller University Laboratory of molecular and Cellular Neuroscience in the ADCC.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG008051-10
Application #
6295499
Study Section
Project Start
1999-07-01
Project End
2000-04-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
10
Fiscal Year
1999
Total Cost
Indirect Cost
Name
New York University
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10016
Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161
Herline, Krystal; Prelli, Frances; Mehta, Pankaj et al. (2018) Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model. Alzheimers Res Ther 10:54
Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Goñi, Fernando; Martá-Ariza, Mitchell; Herline, Krystal et al. (2018) Anti-?-sheet conformation monoclonal antibody reduces tau and A? oligomer pathology in an Alzheimer's disease model. Alzheimers Res Ther 10:10
Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416

Showing the most recent 10 out of 604 publications